Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation turns negative
Q1 FY2026 stock-based compensation was -$987.55K, compared with $2.22M a year earlier. Trailing-twelve-month stock-based compensation was $2.88M. Over 3 fiscal years it compounded at -9.8% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near -$987.55K or moves back toward the trailing-twelve-month quarterly average of $719.96K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.09M USD
- Year-over-year change
- -23.6%
- 4-year CAGR
- -3.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.09M | -23.6% |
| FY2024 | 2024-12-31 | 7.97M | +38.6% |
| FY2023 | 2023-12-31 | 5.75M | -30.6% |
| FY2022 | 2022-12-31 | 8.29M | +16.6% |
| FY2021 | 2021-12-31 | 7.11M | — |
Stock-Based Compensation vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -66.7% is the 9th highest of 10, against a peer median of -5.4%.
- Over three fiscal years its annual growth of -9.8% compares with a peer median of +34.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.34M USD | — | -14.0% | 1556.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M USD | +31.2% | +73.3% | — |
| LTM Mar 2026 | $11.09M USD | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $7.02M USD | -5.4% | +66.3% | — | |
| LTM Mar 2026 | $6.93M USD | -9.1% | +16.8% | 1385.0% | |
GNLXGenelux Corporation | LTM Mar 2026 | $5.84M USD | +8.8% | +34.5% | 72950.0% |
| LTM Mar 2026 | $4.96M USD | +8.1% | +18.3% | — | |
| LTM Mar 2026 | $3.95M USD | -191.3% | — | 1.8% | |
| LTM Mar 2026 | $2.88M USD | -66.7% | -9.8% | — | |
| LTM Dec 2025 | CHF 2.68M CHF | -42.8% | — | 75.0% | |
| LTM Mar 2026 | $1.28M USD | -60.6% | — | 1.9% | |
| Peer median (excluding ALDX) | — | -5.4% | +34.5% | 730.0% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.11M | 8.29M | 5.75M | 7.97M | 6.09M |
| Change in Working Capital | 7.44M | (3.44M) | 861.18K | 5.91M | (5.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 638.06K | (886.08K) | 1.2M | (1.16M) | (21.99K) |
| Other Working Capital | 6.8M | (2.56M) | (343.25K) | 7.07M | (5.16M) |
| Other Non-Cash Items | 409.47K | 283.91K | 339.65K | (1.49M) | (664.43K) |
| Operating Cash Flow | (42.56M) | (56.64M) | (30.33M) | (43.21M) | (33.35M) |
| Capital Expenditures | (7.81K) | (16.32K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 16.32K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (92.94M) | 0 | (96.92M) | (40.26M) |
| Sales of Investments | 0 | 63M | 30M | 52M | 88M |
| Other Investing Activities | 0 | (16.32K) | 0 | 0 | 0 |
| Investing Cash Flow | (7.81K) | (29.95M) | 30M | (44.92M) | 47.74M |
| Debt Repayment | 0 | 0 | (1.04M) | (292.5K) | 0 |
| Common Stock Issued | 189.81M | 1.22M | 305.23K | 121.08K | 1.12M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.68M | 0 | (532.95K) | 0 | (444) |
| Financing Cash Flow | 194.5M | 1.22M | (1.27M) | (171.42K) | 1.12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.93M | (85.37M) | (1.6M) | (88.3M) | 15.51M |
| Free Cash Flow | (42.56M) | (56.65M) | (30.33M) | (43.21M) | (33.35M) |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.